NCT05523089View on ClinicalTrials.gov

The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

September 9, 2022

Primary Completion Date

July 17, 2023

Study Completion Date

July 17, 2023

Conditions
Influenza
Interventions
DRUG

Saline placebo

Sterile normal saline for injection

COMBINATION_PRODUCT

CD388

CD388 liquid for injection

Trial Locations (1)

E1 2AX

hVIVO Services Limited, London

Sponsors

Collaborators (1)

Janssen Pharmaceuticals
All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

lead

Cidara Therapeutics Inc.

INDUSTRY

NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults | Biotech Hunter | Biotech Hunter